Anti‐idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14662
Abstract: Emicizumab markedly shortens the activated partial thromboplastin time (aPTT), resulting in inaccurate measurements of procoagulant and anticoagulant factor activities. We have recently reported that mixtures of two different anti‐idiotype monoclonal antibodies against emicizumab (anti‐emicizumab‐mAbs) allow… read more here.
Keywords: procoagulant anticoagulant; anti idiotype; emicizumab; antibodies emicizumab ... See more keywords